ArticleNephrology (Carlton, Vic.)2025
Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry.
Article in Nephrology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry.Nephrology (Carlton, Vic.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTo evaluate the effectiveness of the third, fourth, and fifth booster doses (rolled out in December 2021, June 2022, and October 2022, respectively) of the coronavirus disease 2019 (COVID-19) vaccine in Japanese haemodialysis patients during the Omicron era.
methodsWe analysed the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) year-end survey data from 2021 to 2022, which included information on the number of vaccinations and the most recent vaccination and infection months. For each month of 2022, the COVID-19 infection and related mortality risks were calculated by vaccination status, followed by logistic regression analyses to estimate adjusted odds ratios (aORs).
resultsOverall, 225 887 patients were analysed, including 13 440 (5.9%), 25 547 (11.3%), 64 242 (28.4%), and 122 658 (54.3%) with ≤ 2, 3, 4, and 5 doses at the end of 2022, respectively. The third dose was significantly correlated with a lower risk of COVID-19 infection in early 2022 (March: aOR 0.53 [0.43-0.64]; April: 0.77 [0.63-0.95]) but was associated with a higher risk during mid-2022, coinciding with the BA.1/2 to BA.5 transition (July: 1.65 [1.39-1.95]; August: 2.37 [2.06-2.71]). The third dose consistently correlated with reduced COVID-19-related mortality. The fourth and fifth doses correlated with lower infection risk and COVID-19-related mortality throughout the period.
conclusionAmong Japanese haemodialysis patients, the third to fifth COVID-19 vaccine doses were associated with reduced infection risk (except in July and August for third doses) and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.